Weeratna Risini D, Makinen Shawn R, McCluskie Michael J, Davis Heather L
Coley Pharmaceutical Group, Suite 200, Ottawa, ON, Canada K2K 3A2.
Vaccine. 2005 Nov 1;23(45):5263-70. doi: 10.1016/j.vaccine.2005.06.024. Epub 2005 Jul 18.
TLR ligands that mimic pathogen associated molecular patterns and activate immune cells via Toll-like receptors (TLRs) are being developed for use in humans as therapy against a variety of diseases as well as vaccine adjuvants. These include imidazoquinoline compounds such as Imiquimod and Resiquimod (R-848) that bind to TLR7 and 8, as well as CpG oligodeoxynucleotides (CpG ODN) that bind to TLR9. This study was aimed at comparing CpG ODN and R-848 for their potential use as vaccine adjuvants and to determine whether there are additive or synergistic effects when they are used together. Using HBsAg as a model antigen in mice, we show CpG ODN to be superior to R-848 for augmenting both humoral and cell mediated immune responses.
模拟病原体相关分子模式并通过Toll样受体（TLRs）激活免疫细胞的TLR配体正被开发用于人类，作为治疗多种疾病的疗法以及疫苗佐剂。这些包括与TLR7和8结合的咪唑喹啉化合物，如咪喹莫特和瑞喹莫德（R-848），以及与TLR9结合的CpG寡脱氧核苷酸（CpG ODN）。本研究旨在比较CpG ODN和R-848作为疫苗佐剂的潜在用途，并确定它们一起使用时是否存在相加或协同作用。在小鼠中使用乙肝表面抗原（HBsAg）作为模型抗原，我们发现CpG ODN在增强体液免疫和细胞介导的免疫反应方面优于R-848。
Zotero 插件